Trial
NCT02406027
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Alzheimer Disease
Intervention
JNJ-54861911, 10 mg
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29